Close
FINDING CURES TOGETHER<sup>SM</sup>
 

Pediatric Cancer in the News


Peter C. Adamson, MD, former PCWG Steering Committee Member, appointed to President Obama's National Cancer Advisory Board

Dr. Peter Adamson, attending Physician in the Division of Oncology at The Children’s Hospital of Philadelphia (CHOP), has been named by President Obama to the National Cancer Advisory Board. Dr. Adamson has been Chair of the Children's Oncology Group, supported by the National Cancer Institute (NCI), since 2010.


 Arceci_Robert.jpgAACR Mourns the Loss of Dr. Robert J. Arceci (1950-2015)


PCWG Chairperson, Garrett Brodeur, MD, Honored with Children's Hospital of Philadelphia Pitcher of Hope Award

Dr. Garrett Brodeur, PCWG Chairperson, was the 2015 recipient of the Children's Hospital of Philadelphia Pitcher of Hope Award. The award is given out by CHOP annually during its Alex's Lemonade Stand "Lemonade Days" events to a recipient in the division of oncology who has positively impacted the field of pediatric oncology.


Margaret Foti, PhD, MD (hc), Receives the 2015 Children’s Champion Award from The Children’s Hospital of Philadelphia

 

Margaret Foti, PhD, MD (hc), chief executive officer of the AACR, was recognized with the Children’s Champion Award for her outstanding pediatric cancer advocacy efforts, at the PCWG town mall meeting in Philadelphia, Sunday, April 19, during the AACR Annual Meeting 2015.  


FDA Approves First Immunotherapy for Children With Cancer

There has been a series of immunotherapy approvals since the end of last year, and following this trend, on March 10, we hit yet another milestone when the U.S. Food and Drug Administration (FDA) approved dinutuximab (Unituxin) for the treatment of pediatric patients with high-risk neuroblastoma. The drug was approved for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Dinutuximab is the first approved immunotherapy for pediatric cancer, and third therapy overall to be first approved for pediatric cancer by the FDA.


Scott M. Lippman, MD Issues Guest Cancer Research Catalyst Blog Post Concerning Cancer Prevention in Children:
"Prophylactic Tonsillectomy in Childhood to Prevent Tonsillitis May Reduce the Risk for HPV-related Oropharyngeal Cancer"


Pediatric Cancer Survivorship Spotlighted in AACR's Cancer Today

Survival for children with cancer has improved dramatically in the past 50 years. However, with this achievement has come increased awareness that successful treatment can come with costs. Research has shown that more than 60 percent of adults treated for cancer when they were children develop at least one chronic health condition.


AACR Releases Cancer Research Catalyst Blog Post on the Importance of Pediatric Cancer Research: "Seizing the Moment: Ongoing Pediatric Cancer Research May Hold Key to Finding Cancer Cures"

Through think tanks, special conferences, and its Pediatric Cancer Working Group, the AACR is taking steps to establish childhood cancer research as a global priority.


Q&A with AACR Pediatric Cancer Working Group Past Chairperson, Dr. Lee J. Helman, on New Cancer Targets and Therapeutics

The National Cancer Institute’s Lee J. Helman, MD, co-chair of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, discusses what to expect this year, and peers into the future of targeted cancer therapies and immunotherapy.


ABC News Twitter Chat on Childhood Cancer

ABC News' Twitter Chat: Conquering Childhood Cancer 

In recognition of Childhood Cancer Awareness Month, the AACR participated in an ABC News Twitter chat, “Conquering Childhood Cancer,” led by Richard Besser, M.D., chief health and medical editor at ABC News. The Twitter chat was held from 1-2 p.m. EDT on Tuesday, Sept. 24, 2013. Leading cancer researcher James Downing, M.D., scientific director, deputy director, and executive vice president at St. Jude Children’s Research Hospital, partnered with the AACR to provide content for live tweets during the chat.

There were a total of 2,373 tweets around and during the Twitter chat. The AACR contributed 45 tweets to the chat and 140 tweets during the chat were retweets of AACR tweets. Dr. Downing and his colleagues at St. Jude provided insightful information for AACR tweets during the chat. All of the 45 AACR tweets were retweeted at least once.

The retweets below are listed in order from most retweeted, indicating the types of content shared during the chat:

RT @AACR For more about how our organization contributes to #pediatric #cancer research, visit http://t.co/jWvZy5hLAm. #abcDrBchat #oncology 

RT @AACR T3 #PediatricCancer is caused by mutations in DNA of normal cells & virtually none are preventable unlike adult cancers #abcDrBchat @StJude

RT @AACR T6 Via @CancerTodayMag, tips for supporting kid w #cancer: be honest, stay positive, love them http://t.co/3S7HYOBnfw #abcDrBchat @StJude

RT @ChildhoodCancer RT @aacr: T1 In 2013, 11,630 children aged 0-14 are projected to be diagnosed with #cancer in the U.S. #abcDrBchat @StJude #oncology

RT @AACR T8 The @AACR #PediatricCancer conference will cover translating basic science into impactful treatments. http://t.co/CIFD2bOgFe #abcDrBchat

RT @abcDrBchat T1 RT @AACR T1 In 2013, 11,630 children aged 0-14 are projected to be diagnosed with #cancer in the U.S. #abcDrBchat

RT @AACR T7 #PediatricCancers are orphan diseases, so there is a limited market for drug development #abcDrBchat @StJude

RT @AACR T6 Make sure your child is being treated at a hospital with experience treating #pediatriccancer #abcDrBchat @StJude

RT @AACR T5 Also increased risk for reproductive problems; chronic heart, lung, & kidney issues; & memory/cognitive difficulties #abcDrBchat @StJude

RT @AACR T5 #Childhoodcancer survivors have increased risk for 2nd cancers #abcDrBchat @StJude

RT @AACR T2 Other signs can be bone pain, vision changes, limping, abnormal lumps, persistent stomach pain, vomiting #abcDrBchat @StJude

RT @AACR T4 Mortality rate declines in ped. #cancer due to improvements in treatment & high rates of #clinicaltrial participation #abcDrBchat @StJude